NewLink Genetics to Participate in the Jefferies 2018 Global Healthcare Conference
Get Alerts NLNK Hot Sheet
Join SI Premium – FREE
AMES, Iowa, May 30, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ: NLNK) announced today that the company will present at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018, at 8:00AM ET.
A live webcast of the presentation will be available on the Company’s website at www.newlinkgenetics.com in the “Investors & Media” section under “Events and Presentations.” An archived edition of the presentation will be available on the Company’s website later in the day.
About NewLink Genetics Corporation
NewLink Genetics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' leading drug candidate, indoximod, is an investigational, orally available small molecule designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Investor Contact:
Lisa MillerDirector of Investor RelationsNewLink Genetics515-598-2555[email protected]
Media Contact:
Sharon CorreiaVP, Integrated CommunicationsLaVoieHealthScience617-374-8800, ext. 105[email protected]
Source: NewLink Genetics CorporationSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Starts Latigo Biotherapeutics (LTGO) at Buy
- Tarana Wireless and Itellum Demonstrate Live 1 Gbps Service at the 13th Latin America Spectrum Management Conference, Paving the Way for Nationwide FWA Coverage in Costa Rica
- Sun Auto Tire & Service Celebrates 600th Store Milestone with Opening of New Plaza Tire Service in Bowling Green, Kentucky
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share